GB-5005

Nov. 9, 2021 12:00 UTC Aleta Biotherapeutics Announces ALETA-001 Presentation at 63rd ASH Annual Meeting NATICK, Mass.--(BUSINESS WIRE)-- Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today announced a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting, to be held in Atlanta, Georgia and in a virtual platform on December 11-14, 2021. The presentation will feature preclinical data that support the upcoming Phase 1/2 clinical trial of ALETA-001 being run in collaboration with Cancer Research UK. Extensive preclinical in vitro modeling demonstrated that ALETA-001 specifically binds to CD20-positive/CD19 negative lymphoma cells. In the presence of anti-CD19 CAR T cells, ALETA-001 mediated cytotoxicity against CD19 negative lymphoma cells at sub-nM concentrations. The administration of ALETA-001 and anti-CD19 CAR T cells in vivo eliminated systemic CD19 negative lymphoma that otherwise produced lethal disease, at doses of ALETA-001 as low as 0.5mg/kg. ALETA-001 is designed to be administered to patients who have received CAR19 T cell therapy and who fail to achieve a complete response at the time of their first clinical evaluation, or who relapse from a complete response thereafter. Clinical trial development is underway in collaboration with Cancer Research UK. Poster Presentation Details: Title: Characterization of Aleta-001, a CAR T Engager Designed to Optimize Responses and Prevent Relapses from CAR-19 Therapy Presenter: Paul D. Rennert, PhD Presentation Date & Time: Saturday, December 11, 2021, 5:30 PM ET Session Name: 703. Cellular Immunotherapies: Basic and Translational Abstract Number: 1713 About Aleta Biotherapeutics Our mission is to create cell therapeutics that provide robust and durable clinical benefit for patients suffering from advanced hematologic cancers and refractory solid tumors. Aleta's CAR-T Engager technology incorporates potent multi-antigen targeting, optimal T cell fitness, and persistence to aggressively attack cancers. We use this technology to build programs that solve specific clinical issues, including cell therapy relapses due to antigen loss and the challenge of overcoming solid tumor heterogeneity. Our lead development program has won landmark clinical support from Cancer Research UK and will enter Phase1/2 trials in 2022. To discover more about our mission, technologies and pipeline please visit . To learn more about the work being done by Cancer Research UK please visit .